Products - Thyroid cancer | Topic | NICE

Showing 1 product

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC